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are responsible for other sporadic 
and familial forms of the disease 
and could lead to the identification 
of new susceptibility genes.
Several types of protein-protein 
interaction maps have been devel-
oped. These include specific interac-
tion networks, such as the ataxia net-
work presented by Lim et al. (2006), 
which generate a huge number of 
gene modifier candidates that may 
participate in or regulate patho-
genic processes. Other networks 
have described interactions across 
the entire proteome in model organ-
isms such as yeast, Drosophila, and 
Caenorhabditis elegans. Approaches 
to systematically map human protein 
interactions have also been under-
taken (Rual et al., 2005; Stelzl et al., 
2005). These networks are certainly 
not independent and should be con-
sidered together as they will contrib-
ute in a complementary manner to 
understanding the mechanisms that 
control cellular behavior in develop-
ment and disease. Indeed, thousands 
of interactions have been described, 
and now the challenge is to conduct 
comparative analysis of these inter-
actomes to organize these data. 
We also need to further address the 
dynamics of these systems. Thus, it 
will be critical to determine when and 
where these interactions occur and 
how they are regulated both within a 
given cell and in the context of whole 
tissues.
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In this issue of Cell, Knight et al. (2006) present a detailed pharmacological analysis of 
the PI3 kinase (PI3-K) family using small molecule inhibitors. They conclude that p110α, a 
PI3-K isoform, has a critical role in insulin signaling. In a related Cancer Cell paper, Fan et 
al. (2006) show that blocking activation of both p110α and the kinase mTOR with a small 
molecule inhibitor limits the growth of gliomas.Validating therapeutic targets is an 
inherently difficult undertaking. The 
sheer number of potential drug tar-
gets in the postgenomic era makes 
validation the rate-limiting step in 
drug development (Lindsay, 2003). 
Not surprisingly, many more thera-
peutic candidates fail because of a 
lack of efficacy rather than because of safety concerns. Owing to the 
astronomical costs of drug develop-
ment, a high threshold is set for the 
validation of new drug targets. The 
ideal drug target is one whose inhibi-
tion leads to the desired therapeutic 
outcome and does not lead to dele-
terious so-called mechanism-based 
side effects. Mechanism-based side Cell 125effects arise from the inhibition of the 
normal function of an enzyme, which 
is separate from its disease-associ-
ated function. But for any given target, 
the likelihood of a simple pharmaco-
logical landscape with no off-target 
activity due to inhibition of homolo-
gous proteins and no mechanism-
based side effects is low. However, , May 19, 2006 ©2006 Elsevier Inc. 647
in two recent studies, including one 
in this issue (Fan et al., 2006; Knight 
et al., 2006), Kevan Shokat and col-
leagues demonstrate that preclinical 
validation of therapeutic targets can 
be accomplished with the right set of 
tools and a thorough understanding 
of the target’s function in a complex 
biological system.
As targets for drug development, 
lipid kinases have lagged behind the 
protein kinases, but this trend may 
be set to change. Three new stud-
ies identifying specific and parallel 
functions of lipid kinases may open 
the door to the development of drugs 
targeting specific phosphoinositide-
3′-OH kinase (PI3-K) family mem-
bers. In this issue, Knight et al. (2006) 
report a detailed pharmacological 
analysis of PI3-K isoforms using 
small molecule inhibitors. In addi-
tion, recent publications in Nature 
(Foukas et al., 2006) and Cancer Cell 
(Fan et al., 2006) describe advances 
in understanding PI3-K function and 
in the development of treatments 
based on the selective inhibition of 
PI3-K isoforms.
The mammalian PI3-K family con-
sists of eight catalytic isoforms (Hen-
nessy et al., 2005). In addition, five 
genes encode regulatory subunits. 
More distant family members include 
the phosphoinositide-4′-OH kinases 
(PI4-K) and the ATM, ATR, DNA-PK, 
and mTOR protein kinases. Varied 
patterns of PI3-K expression, abun-
dance, and subunit composition as 
well as overlapping and redundant 
functions have made PI3-Ks diffi-
cult to exploit as therapeutic targets. 
Given this embarrassment of riches, 
it has been difficult to determine 
exactly which isoforms uniquely per-
form specific functions. Gene knock-
out studies in mice have shed some 
light on the topic, but all too often, 
the phenotypes observed in these 
experiments fall at either extreme and 
are either very mild (for example, with 
expression of p110γ with an inactive 
kinase) or are embryonic lethal (such 
as knockout of either p110α or p110β) 
(Vanhaesebroeck et al., 2005).
Small molecules have several 
advantages as tools for validating 
potential therapeutic targets. First 648 Cell 125, May 19, 2006 ©2006 Elseviand foremost, unlike the validation 
strategies using RNAi or gene disrup-
tion, small molecules can themselves 
act as drugs. And as allelic replace-
ment studies with p110γ have shown, 
the absence of a target due to gene 
disruption may not be equivalent to 
inhibition of a target (for example, 
replacement of the gene with an 
allele encoding an inactive kinase) 
(Patrucco et al., 2004). Also, small 
molecules allow for temporal and 
incremental control over the activity 
of the target. Finally, small molecules 
can be exquisitely specific, inhibiting 
only one among many related tar-
gets, or they can be highly selective, 
inhibiting a defined subset of targets. 
In the past, only panselective PI3-K 
inhibitors such as LY-294002 and 
the natural product wortmannin have 
been available for study. This has 
limited the use of small molecules to 
validate particular PI3-K isoforms as 
potential therapeutic targets.
Knight et al. (2006) present a 
detailed interrogation of PI3-K and 
related kinases using a diverse panel 
of PI3-K inhibitors. The authors 
assembled a collection of PI3-K 
inhibitors based on the literature 
and on patents granted as well as 
new compounds synthesized in their 
laboratories. A panel of 15 kinases 
was tested using inhibitors from nine 
distinct chemical classes. One of 
these compounds was highly selec-
tive, such that its IC50 (the concentra-
tion of inhibitor at which the enzyme 
activity is 50% of its maximum) for 
the kinase most affected by the 
compound was 400 times lower than 
the IC50 for the second-most sensi-
tive kinase. However, most inhibitors 
showed a moderate selectivity of 
2- to 10-fold. In any case, the panel 
of compounds used by Knight et 
al. (2006) is of sufficient structural 
diversity to provide inhibitors that are 
at least partially selective for each 
of the p110 isoforms of PI3-K. Using 
principal component analysis, the 
authors uncovered a cryptic relation-
ship between p110α and DNA-PK. 
In spite of limited primary-sequence 
homology, the two kinases are phar-
macological homologs, or pharma-
logs, meaning that inhibitors of one er Inc.kinase usually target the other as 
well. This type of analysis provides a 
means to anticipate off-target activ-
ity and undesired side effects.
In order to gain insight into the 
molecular bases for the selectivity 
of the inhibitors, Knight et al. (2006) 
determined the cocrystal struc-
tures of p110γ bound to three differ-
ent inhibitors: PIK-39 (selective for 
p110δ), PIK-90 (selective for p110α), 
and PIK-93 (selective for p110γ). In 
addition, structural models were cre-
ated of p110 bound to PI-103 (selec-
tive for DNA-PK), PIK-108 (selective 
for p110β) and KU-55933 (selective 
for ATM). These structural studies 
reveal a delicate balance between 
affinity and selectivity. Nonselec-
tive, high-affinity inhibitors occupy 
the ATP binding site, rely on similar 
electrostatic and steric interactions, 
and access a hydrophobic pocket 
adjacent to the ATP site. In contrast, 
highly specific inhibitors (such as 
PIK-39) rely on a hydrogen bond to 
the backbone amide of Val882, a core 
interaction that is shared by all PI3-
K inhibitors and ATP, but also have 
contacts outside of the ATP binding 
pocket. Specifically, Met804 may act 
as a selectivity switch that blocks 
access to a hydrophobic pocket 
between it and Trp812. Only PIK-39 
has an architecture that is sufficiently 
complementary to induce a confor-
mational rearrangement of Met804 
and allow an energetically favorable 
interaction within the hydrophobic 
pocket.
It is known that PI3-K plays a key 
role in insulin signaling by linking the 
insulin receptor and insulin-receptor 
substrate (IRS) proteins to down-
stream effectors (White, 2003). The 
nonselective inhibitors wortmannin 
and LY-294002 are capable of block-
ing all insulin-induced lipid kinase 
activity in IRS1 or IRS2 complexes. 
However, the lack of selectivity for 
these compounds precludes iden-
tification of specific PI3-K isoforms 
as targets in the insulin signaling 
cascade. Homozygous deletion 
of p110α or p110β in mice leads to 
embryonic lethality, whereas the 
heterozygotes show no metabolic 
defects (Brachmann et al., 2005). A 
recent publication in Nature (Fou-
kas et al., 2006) describes a mouse 
model in which the activity of p110α 
is attenuated. Foukas et al. (2006) 
created a transgenic mouse in which 
one allele of p110α has no kinase 
activity and the other is the normal 
wild-type allele. This mouse shows 
decreased insulin signaling, glucose 
intolerance, and increased formation 
of adipose tissue. Thus, the authors 
conclude that p110α is the PI3-K iso-
form required for insulin signaling. 
Remarkably, using the panel of spe-
cific and selective PI3-K inhibitors, 
Knight et al. (2006) come to the same 
conclusion. Knight et al. (2006) show 
that, although multiple isoforms are 
expressed in adipocytes and myo-
tubes, in both systems, p110α is the 
primary isoform required for insulin 
signaling. Interestingly, p110δ and/
or p110γ may provide an additional 
source of inositide triphosphates in 
myotubes but not in adipocytes. Inhi-
bition of both p110δ and p110γ has 
no effect on the ability of the p110α 
inhibitor PIK-75 to block activation of 
Akt kinase in adipocytes. In contrast, 
inhibition of p110δ and p110γ works 
synergistically with PIK-75 to block 
the activation of Akt kinase in myo-
tubes.
The PI3-K family is known to pro-
mote cell growth and survival and 
is believed to play a role in cancer. 
Evidence for the role of PI3-K in can-
cer has been demonstrated in three 
ways. First, the PI3-K signal that is 
stimulated by growth factors is nega-
tively regulated by the dual-specific-
ity phosphatase and tensin homolog 
(PTEN), which is inactivated through 
mutation or transcriptional silencing 
in a significant percentage of spo-
radic tumors. Second, altered Akt 
kinase activity, a downstream effec-
tor of PI3-K signaling, also occurs 
in a variety of epithelial and hema-
topoietic malignancies. Third, muta-
tions or activating translocations in 
p110α, although rare, have also been 
documented. Thus, there is much 
evidence in support of the conclu-
sion that aberrant activation of Akt 
through PI3-K allows cancer cells 
to bypass growth-limiting controls (Cully et al., 2006). Until recently, 
however, the lack of isoform-spe-
cific inhibitors has largely precluded 
validating PI3-K as a therapeutic tar-
get for the treatment of cancer. In a 
recent paper in Cancer Cell, Fan et al. 
(2006) used the same diverse collec-
tion of PI3-K inhibitors described by 
Knight et al. (2006) to survey a panel 
of glioma cell lines. The panselec-
tive PI3-K inhibitor LY-294002 blocks 
Akt phosphorylation and causes cell 
death at similar concentrations. In 
contrast, a specific inhibitor of p110α 
(PI-103) blocks Akt phosphorylation 
and causes a G0/G1 cell-cycle arrest 
at a concentration that is 50-fold 
lower than that required to induce 
cell death. An inhibitor of the p110β 
and p110δ isoforms (TGX-286) also 
blocks Akt phosphorylation but does 
not induce cell-cycle arrest. On the 
basis of the pharmacological sur-
vey of PI3-K isoforms presented by 
Knight et al. (2006), Fan et al. (2006) 
hypothesized that concurrent inhibi-
tion of p110α and mTOR, a unique 
property of PI-103, was required for 
growth inhibition. Using a combi-
nation of rapamycin, an inhibitor of 
mTOR, and an inhibitor of p110α that 
does not target mTOR (PIK-90), the 
authors showed this to be the case. 
Moreover, PI-103 inhibits prolifera-
tion of glioma cells in vivo. U8MG gli-
oma cells that express an activated 
form of the epidermal growth-factor 
receptor were implanted into immu-
nodeficient mice. Tumor-bearing 
mice received PI-103 or vehicle as a 
control. The dual-specificity p110α/
mTOR inhibitor blocked tumor growth 
by preventing Akt phosphorylation 
and inducing cell-cycle arrest.
The findings that inhibition of 
p110α (and mTOR) in cancer cells 
causes growth inhibition and that 
blocking activation of p110α in adi-
pocytes leads to inhibition of insulin 
signaling raise an important and trou-
bling question: Would diabetes be a 
side effect of a cancer chemotherapy 
directed at inhibiting p110α? The 
study by Foukas et al. (2006) sug-
gests that the answer is no. Although 
adult mice with attenuated p110α 
activity displayed all of the hallmarks Cell 125of impaired insulin signaling, they did 
not progress to diabetes.
The term “off-target activity” 
bears a negative connotation. How-
ever, it is becoming increasingly 
apparent that some off-target activi-
ties can be beneficial and, in many 
cases, may be preferable to no off-
target activity at all. PI-103 blocks 
cancer cell growth by targeting two 
kinases. It is likely that many “drugs 
of the future” will exploit synergisms 
between two or more targets, and, 
as complex biological relationships 
among members of enzyme families 
are uncovered, parallel or synthetic 
interactions may identify efficacious 
target combinations. The two recent 
studies using small molecule inhibi-
tors of the PI3-K family demonstrate 
that, even with imperfect tools, a 
detailed and accurate understanding 
of a complex biological system and 
target validation can be obtained.
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